Trending NewsTrending NewsNASDAQ:UNCY Unicycive Therapeutics (UNCY) Stock Price, News & Analysis $3.89 -0.05 (-1.27%) Closing price 10/23/2026 04:00 PM EasternExtended Trading$3.89 +0.00 (+0.08%) As of 10/23/2026 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Unicycive Therapeutics Stock (NASDAQ:UNCY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Unicycive Therapeutics alerts:Sign Up Key Stats Today's Range$3.71▼$4.0250-Day Range$3.36▼$5.6352-Week Range$3.35▼$8.74Volume1.21 million shsAverage Volume1.06 million shsMarket Capitalization$108.36 millionP/E RatioN/ADividend YieldN/APrice Target$18.25Consensus RatingModerate Buy Company Overview Unicycive Therapeutics, Inc. (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis. Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream. The company is evaluating OLC as a potential treatment for patients with chronic kidney disease who require dialysis and may benefit from additional phosphate-management options. The company’s activities have centered on clinical development and regulatory preparation rather than commercial product sales. Unicycive is based in the United States and has conducted its development work in collaboration with clinical and research organizations. Shalabh Gupta, M.D., serves as the company’s chief executive officer. Because OLC remains an investigational product, the company does not currently have an established commercial product portfolio or broad geographic sales operations.AI Generated. May Contain Errors. Read More Unicycive Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreUNCY MarketRank™: 2.42334588488 of 5 starsUnicycive Therapeutics scored higher than 48% of companies evaluated by MarketBeat, and ranked 522nd out of 902 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingUnicycive Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on no strong buy ratings, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialUnicycive Therapeutics has a consensus price target of $18.25, representing about 369.2% upside from its current price of $3.89.Amount of Analyst CoverageUnicycive Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Unicycive Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Unicycive Therapeutics are expected to grow in the coming year, from ($1.16) to $1.44 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Unicycive Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Unicycive Therapeutics is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioUnicycive Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Unicycive Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted18.54% of the float of Unicycive Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnicycive Therapeutics has a short interest ratio ("days to cover") of 5.74.Change versus previous monthShort interest in Unicycive Therapeutics has recently increased by 15.50%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUnicycive Therapeutics does not currently pay a dividend.Dividend GrowthUnicycive Therapeutics does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment0.01 News SentimentUnicycive Therapeutics has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Unicycive Therapeutics this week, compared to 7 articles on an average week.Search InterestOnly 2 people have searched for UNCY on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Unicycive Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Unicycive Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders6.03% of the stock of Unicycive Therapeutics is held by insiders.Percentage Held by Institutions40.42% of the stock of Unicycive Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Unicycive Therapeutics' insider trading history. Receive UNCY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Unicycive Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. UNCY Stock News HeadlinesUNCY DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCYOctober 24 at 7:02 PM | globenewswire.comUnicycive Deadline: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitOctober 24 at 10:27 AM | prnewswire.comTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of Saudi Arabia's largest oil field, with potential to last two million years. While the One Big Beautiful Bill Act eliminated federal credits for solar, wind, and EVs, this energy source was reclassified alongside oil and nuclear power and given eight years of tax credits. Google signed a 15-year contract, and Bill Gates committed $100 million. One company controls the entire supply chain behind this discovery. | Behind the Markets (Ad)Unicycive Therapeutics announces FDA acceptance of oxylanthanum carbonate NDA resubmission, PDUFA date of March 25, 2027October 23 at 2:39 PM | msn.comAverage analyst price target for Unicycive Therapeutics rises 12.32% to $32.54October 23 at 2:39 PM | msn.comWhat's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff DeadlineOctober 23 at 2:10 PM | prnewswire.comWhat Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G.October 22 at 2:40 PM | prnewswire.comUNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the FirmOctober 22 at 10:11 AM | prnewswire.comSee More Headlines UNCY Stock Analysis - Frequently Asked Questions How have UNCY shares performed this year? Unicycive Therapeutics' stock was trading at $5.77 at the start of the year. Since then, UNCY shares have decreased by 32.6% and is now trading at $3.89. How were Unicycive Therapeutics' earnings last quarter? Unicycive Therapeutics, Inc. (NASDAQ:UNCY) issued its earnings results on Wednesday, August, 12th. The company reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.47) by $0.41. When did Unicycive Therapeutics' stock split? Unicycive Therapeutics's stock reverse split on the morning of Friday, June 20th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 19th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Unicycive Therapeutics IPO? Unicycive Therapeutics (UNCY) raised $25 million in an initial public offering on Tuesday, July 13th 2021. The company issued 4,600,000 shares at $5.00-$6.00 per share. Roth Capital Partners served as the underwriter for the IPO and EF Hutton (formerly Kingswood Capital Markets) was co-manager. How do I buy shares of Unicycive Therapeutics? Shares of UNCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Unicycive Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Unicycive Therapeutics investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SoundHound AI (SOUN), Tonix Pharmaceuticals (TNXP), Broadcom (AVGO), Cabaletta Bio (CABA) and IonQ (IONQ). Company Calendar Last Earnings8/12/2026Today10/24/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 UNCY's financial health is in the Yellow zone, according to TradeSmith. UNCY has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:UNCY CIK1766140 Webwww.unicycive.com Phone650-351-4495FaxN/AEmployees22Year FoundedN/APrice Target and Rating Average Price Target for Unicycive Therapeutics$18.25 High Price Target$25.00 Low Price Target$13.00 Potential Upside/Downside+369.2%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($1.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$26.56 million Net MarginsN/A Pretax MarginN/A Return on Equity-91.50% Return on Assets-61.47% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.81 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.41 per share Price / Book2.76Miscellaneous Outstanding Shares27,855,000Free Float26,175,000Market Cap$108.36 million OptionableOptionable Beta1.83 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:UNCY) was last updated on 10/23/2026 by MarketBeat.com Staff. From Our PartnersThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that l...Profits Run | SponsoredThe $100 Stock Behind Elon's Next MoveA small, publicly traded supplier trading under $100 a share has reportedly worked alongside Elon Musk for mor...Paradigm Press | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
